Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Helix BioPharmaHBPCF 33 Net Cash per Share is $-0.04 as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 33/100. Among 795 Biotechnology companies, Helix BioPharma ranks worse than 125786.04% on this metric.
The historical rank and industry rank for Helix BioPharma's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Helix BioPharma was 212.50. The lowest was 22.00. And the median was 51.25.
HBPCF's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.3 * Ranked among companies with meaningful Price-to-Net-Cash only.
Helix BioPharma (OTCPK:HBPCF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Helix BioPharma Net Cash per Share Related Terms
Helix BioPharma Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBPCF vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Helix BioPharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Helix BioPharma's Net Cash per Share for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a Net Cash per Share of $-0.04 as of Apr. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Helix BioPharma and its competitors. Over the past decade, Helix BioPharma's Net Cash per Share has ranged from 22.00 to 212.50. According to the industry distribution chart, Helix BioPharma ranks #999999 out of 795 companies in the Biotechnology industry.
Is Helix BioPharma's Net Cash per Share too high?
Helix BioPharma's current Net Cash per Share is $-0.04. Over the past 10 years, this metric has ranged from a low of 22.00 to a high of 212.50. Based on the distribution chart, Helix BioPharma ranks #999999 out of 795 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helix BioPharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #999999 out of 795 companies for Net Cash per Share. This places Helix BioPharma in the lower half of its industry. The industry median Net Cash per Share is 5.30. Historically, Helix BioPharma's own Net Cash per Share has ranged from 22.00 to 212.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.30, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Helix BioPharma and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current Net Cash per Share is $-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Net Cash per Share of $-0.04. The current Net Cash per Share is $-0.04. Helix BioPharma's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Net Cash per Share is $-0.04 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
33GF Score
Get the complete analysis for HBPCF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
